Results 1 to 10 of about 95,889 (290)
MAMC Journal of Medical Sciences, 2021 Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six decades. In light of the recent outbreak of mucormycosis (black fungus) cases during the second coronavirus disease 2019 wave in India, the relevance of ...
Sahil Kumar, Vandana Roy
doaj +3 more sources
Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached? [PDF]
Journal of Fungi, 2020 As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds.
Maria Aigner, Cornelia Lass-Flörl
doaj +3 more sources
Experience of research nurses with oral encochleated amphotericin B for treatment of cryptococcal meningitis in a resource-limited setting [PDF]
BMC Infectious DiseasesBackground Besides the commonly used intravenous formulations of amphotericin B, an oral nanocrystal amphotericin B (MAT2203) formulation is being evaluated for efficacy to treat invasive fungal infections.
Cynthia Ahimbisibwe +8 more
doaj +2 more sources
Evaluation and testing of polymethylmetacrylic (PMMA) bone cements with admixed Amphotericin B [PDF]
Journal of Orthopaedic Surgery and ResearchBackground Amphotericin is admixed to Polymethylmethacrylic (PMMA) spacers for fungal periprosthetic joint infections (PJI) during two-stage exchanges. We aimed to analyse the mechanical properties of PMMA cement with admixed Amphotericin B.
Florian A. Frank +6 more
doaj +2 more sources
Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis [PDF]
MicroorganismsBackground: Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients. Objectives: We aim to compare the real-world effectiveness and safety of isavuconazole with those of amphotericin B in patients ...
Jiayuan Qin +6 more
doaj +2 more sources
Amphotericin B induced pancytopenia
Journal of Family Medicine and Primary Care, 2022 Amphotericin B (AMB) has been the irreplaceable drug of choice for countless fungal and protozoal infections. One of the lesser-known adverse effects of AMB is Pancytopenia - very rare with very few cases reported - most commonly observed following ...
Esha Vaish +3 more
doaj +1 more source
Liposomal amphotericin B—the future [PDF]
Journal of Antimicrobial Chemotherapy, 2022 AbstractAdvances in medicine have led to a growing number of people with compromised or suppressed immune systems who are susceptible to invasive fungal infections. In particular, severe fungal infections are becoming increasingly common in ICUs, affecting people within and outside of traditional risk groups alike.
M Hoenigl +4 more
openaire +6 more sources
Liposomal amphotericin B—the past [PDF]
Journal of Antimicrobial Chemotherapy, 2022 Abstract The discovery of amphotericin B, a polyene antifungal compound, in the 1950s, and the formulation of this compound in a liposomal drug delivery system, has resulted in decades of use in systemic fungal infections. The use of liposomal amphotericin B formulation is referenced in many international guidelines for the treatment of ...
R J Brüggemann +2 more
openaire +3 more sources
An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety. [PDF]
PLoS ONE, 2016 Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage.
Armando Antillón +21 more
doaj +1 more source